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ABSTRACT 
Common variable immunodeficiency (CVID) is the most frequently 
encountered primary immunodeficiency disorder in clinical practice and is a 
cause of significant morbidity and mortality for patients. The main clinical 
features are hypogammaglobulinemia, recurrent infections and autoimmune 
disorders. Unlike the majority of primary immunodeficiency disorders, 
pinpointing a specific genetic association has been challenging.  
The objective of this work was to use next generation sequencing (NGS) 
technology in the form of whole exome sequencing (WES) to identify genetic 
associations with CVID. 
Candidate patients were selected based on parental consanguinity and 
availability of clinical specimens from them and their family members. Whole 
exome sequencing was performed and identified potential mutations which 
were confirmed by Sanger sequencing, followed by characterization of the 
novel mutations by immunological techniques. 
In Paper I, genetic analysis identified four novel CD27 mutations: homozygous 
missense mutations C96Y and R78W; heterozygous nonsense C10X; and 
compound heterozygous W8X-R107C resulting in a clinical phenotype of 
CD27 deficiency. 
In Paper II, whole exome sequencing revealed a novel W56X mutation in the 
RAC2 gene resulting in a CVID-like phenotype with prominent autoimmune 
disease. Newly identified abnormalities of neutrophil granules were identified 
by transmission electron microscopy. 
In Paper III, five novel mutations in the LRBA gene resulting in varied clinical 
phenotypes were presented in the context of a review of all published cases, 
thus providing a clinical summary. 
In conclusion, this work has shown the validity of employing whole exome 
sequencing in identifying genetic associations with CVID and CVID-like 
disease; and has provided a better overview of the diverse clinical phenotypes 
associated with mutations in CD27, RAC2 and LRBA and their resultant protein 
deficiencies. 
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1 INTRODUCTION 
 
1.1 PRIMARY ANTIBODY DEFICIENCY 
 
The spectrum of the disease phenotypes related to disorders of immunity 
encountered in clinical practice are numerous and lead to much suffering for 
patients [1-4]. Primary immunodeficiency disorders (PIDs) occur as a result 
of mutations affecting genes related to the function of proteins and cells of 
the immune system [5-9]. Primary antibody deficiencies (PADs) represent 
the most common forms of PIDs according to the majority of studies and 
national registries [2, 3, 10-38]. Alternatively, some studies suggest that 
PADs are less frequent than other PIDs in those populations [39-45]. 
Among PADs, the most common clinical phenotype is selective IgA 
deficiency (IgAD), followed by common variable immunodeficiency 
(CVID), a disorder characterized by hypogammaglobulinema, a varied 
phenotype and an onset that might range from early childhood to late 
adulthood [2, 46-49].  
Common variable immunodeficiency comprises a heterogeneous group of 
disorders with a wide spectrum of immunological and clinical features [2, 
50, 51]. Common clinical and laboratory characteristics include 
hypogammaglobulinemia, inadequate response to antigen challenge and 
recurrent infections (mostly of the respiratory tract) [52-59]. 
However, other clinical features also occur, including autoimmune disorders 
(e.g., autoimmune cytopenias, autoimmune hepatitis, primary biliary 
cirrhosis), inflammatory bowel disease (IBD), IBD-like disease, nodular 
lymphoid hyperplasia (NLH) and liver disease/abnormal liver function tests 
(LFTs) [2, 53, 58, 60, 61]. 
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1.2 PREVALENCE, DIAGNOSIS AND ETIOLOGY/GENETICS OF 
CVID 
 
Precise data on the prevalence of CVID is lacking, but estimates are between 
1:10,000 and 1:100,000 of the population worldwide suffers from the 
disease, with no predilection for race [62-64], making it the most common 
symptomatic primary immunodeficiency encountered in clinical practice 
[22, 65]. Most cases of CVID are sporadic, but approximately ten percent 
demonstrate familial clustering [66]. 
Establishing a diagnosis of CVID (and subsequent treatment plans) is not 
always a simple task [2, 67-69], as reflected by the latest Working 
Definitions for Clinical Diagnosis of PID from the European Society for 
Immunodeficiencies (ESID) [70].  
The current diagnostic criteria are as follows: 
 
1. At least one of the following: 
•بIncreasedبsusceptibilityبtoبinfection 
•بManifestations of autoimmune disease 
•بGranulomatousبdisease 
•بUnexplainedبpolyclonalبlymphoproliferation 
•بAffectedبfamilyبmemberبwithبantibodyبdeficiency 
2. AND marked reduction of IgG and IgA levels with or without low 
IgM levels (measured at least twice; less than 2 standard deviations of 
the normal levels for age); 
3. AND at least one of the following: 
•بPoorبantibodyبresponseبtoبvaccinesب(and/orبabsentب
isohaemagglutinins); 
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•بLowبproportions of switched memory B cells (<70% of age-related 
reference value) 
4. AND secondary causes of hypogammaglobulinaemia have been 
excluded 
5. AND a diagnosis should be established after the 4th year of life 
(however, symptoms may occur before the age of 4 years) 
6. AND the absence of profound T cell deficiency, which is defined as  
the presence of two out of the following three parameters (y=year of 
life): 
•بCD4+ T cell count/microliter:  
 2y-6y <300,  
 6y-12y <250,  
 Above 12y <200 
•بProportionبof naive CD4+ T cells:  
 2y-6y <25%,  
 6y-16y <20%, 
 Above 16y <10% 
•بAbsent T cell proliferation  
 
The significant variation in clinical features, challenges in 
establishing/unifying laboratory cut-off  values across different populations 
and the considerable overlap that exists between other conditions (e.g., class-
switch recombination (CSR) defects) and CVID, has led to the designation 
“CVID-likeبdisease”بforبcasesبthatبareبinitiallyبlabelledبasبCVIDبorبthatبdoب
notبfulfillبtheب‘official’بdiagnosticبcriteriaب[71, 72]. 
Investigations into the underlying etiology of CVID have led to the 
identification of several genes associated with CVID and CVID-like disease. 
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Many studies conducted in the search for genetic causes of CVID have been 
performed on mixed cohorts of IgAD and CVID patients, as both disorders 
may occur in the same kindred or progress from IgAD to CVID [66, 73-75].  
Genetic defects identified thus far include mutations in the genes encoding 
ICOS (inducible costimulator) [76-81], TNFRSF13B (tumor necrosis factor 
receptor superfamily member 13B), also known as TACI (transmembrane 
activator and CAML interactor) [82-84], BAFFR (B-cell activating factor 
receptor) [85], IL-21 (interleukin-21) [86], MSH5 [87], CD20 [88], LRBA 
(lipopolysaccharide responsive beige-like anchor protein) [51], IRF2BP2  
(Homo sapiens interferon regulatory factor 2 binding protein 2) [89],  
CTLA4 (cytotoxic T-lymphocyte-associated protein 4) [90], CLEC16A (C-
type lectin domain family 16, member A) [91], CD27 [92, 93], RAG1 
(recombination-activating gene 1) [94], JAK3 [95], ITPKB (inositol 1,3,4, 
trisphosphateبkinaseبβ)ب[96], CD19 [97], CD21 [98], PI3KR1 [99] and CD81 
[100]
 
.  
However these mutations only account for the etiology of approximately 
10% of CVID patients, and the potential genetic associations remain largely 
unknown in the vast majority of cases [50, 51, 101, 102].  
Conventional approaches for determining the potential genetic etiologies for 
PIDs have included the candidate gene approach, conventional Sanger 
sequencing, polymorphism analysis, positional cloning, somatic cell-fusion 
experiments, fluorescence in situ hybridization (FISH),  genetic linkage 
and/or homozygosity mapping [92, 98, 103-116]. Genome-wide association 
studies (GWAS) have also been employed [91, 117, 118].  
The advent of more advanced technologies, such as next-generation 
sequencing (NGS), coupled with enhanced algorithms for bioinformatics 
have enabled a much wider approach for genetic analysis and has been 
successful in the search for genetic associations with PIDs [119-128]. The 
process has subsequently become less labor-intensive, more cost-effective 
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and, from a clinical standpoint, offers shorter turn-around times for reaching 
definitive or tentative genetic diagnoses in patients with immunodeficiencies 
by using whole exome sequencing (WES) or whole genome sequencing 
(WGS) alone, or combined with conventional methods [99, 118, 121, 122, 
125, 126, 129-158]. 
 
1.3 GENETIC LINKAGE ANALYSIS 
 
Genetic linkage studies have been conducted in the context of CVID/IgA 
deficiency with earlier studies focusing on the major histocompatibility 
complex (MHC) region on chromosome 6 and mostly show linkage without 
pinpointing the exact location of the putative disease-related gene in the 
MHC region [159-161]. The MHC susceptibility locus was designated 
IGAD1 [162, 163]. 
Following these studies, genome-wide linkage studies were performed. An 
analysis of 210 IgA deficiency/CVID families identified HLA-DQ/DR as the 
major IGAD1 locus [164]. Further genome-wide linkage analysis of 101 
families with 383 marker loci showed the highest linkage scores at the short 
arm of chromosome 6, and these scores were not obtained in any other 
location of the genome [164]. Subsequent re-analysis specifically searching 
for CVID-associated loci (40 families with a minimum of one member 
affected by CVID) showed a susceptibility locus on the long arm of 
chromosome 16 and the WWOX (WW domain-containing oxidoreductase) as 
a putative CVID-associated gene, but no mutations were detected upon 
sequencing [73]. 
 
Another study identified genetic linkage of autosomal dominant CVID to 
chromosome 4q in a genome-wide scan of a five-generation family with five 
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cases of IgAD, six cases of CVID, and three cases of 
dysgammaglobulinaemia [74]. Further extension of the study to include 32 
families (with at least one case of CVID and another case with CVID or 
IgAD) supported the linkage to chromosome 4q. Potential candidate genes in 
the region (NFκB1, SCYE, CASP6, DAPP1, BANK1) were sequenced in a 
single individual from the large family but no mutations were identified. 
 
1.4 GWAS AND NGS IN CVID 
 
CVID shows heterogeneity in both clinical features and in immunological 
phenotype which would point to a high probability of a complex polygenic 
etiology. Genetic mutations have been identified in a small proportion of 
CVID cases. 
Most studies have focused on monogenic defects causing or contributing to a 
CVID or CVID-like phenotype, as well as a limited number of genetic 
linkage studies. Advances in technology have allowed high-throughput 
genome-wide single nucleotide polymorphism (SNP) genotyping. 
Recently, Abolhassani et al, using a combination of homozygosity mapping 
and whole exome sequencing, identified a hypomorphic recombination-
activating gene 1 (RAG1) mutation in a patient with CVID-like disease [94]. 
Mutations in LRBA were identified in five cases of early-onset 
hypogammaglobulinemia with autoimmunity and IBD-like disease using 
genome-wide SNP typing, DNA sequencing and genetic linkage analysis 
[51]. Additional novel LRBA mutations were identified using WES and 
confirmatory sequencing in CVID-like disease and IBD-like disease [142, 
149].  
Li et al. compared 778 CVID cases with approximately 11,000 controls 
across 123,127 SNPs using the Immunochip (a genotyping array with dense 
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coverage of SNPs across 186 known disease loci identified in 12 immune-
mediated diseases), thus identifying a novel CVID susceptibility locus 
harboring CLEC16A (C-Type Lectin Domain Family 16, Member A) [91]. 
van Schouwenburg et al. used whole genome sequencing and RNA 
sequencing (RNAseq) on 34 patients of Caucasian origin with sporadic 
CVID who fulfilled the ESID diagnostic criteria at the time of enrollment 
[165]. Their cohort included 29 patients who were analyzed in the study by 
Orange et al [117]. The study identified 43 potentially pathogenic rare 
variants of which 39 were located in the MHC region. Their results 
corroborated earlier findings of variation in TNFRSF13B, TNFRSF13C and 
NLRP12 [82, 166-169]; and identified variants that would potentially 
produce a CVID-like phenotype by affecting B-cell receptor (BCR) function, 
including IKBKB, CD79a, BTK, KRAS, ARID3A, INPP5D, BANK1, BLK, 
GAB2, BTK, BLK and ARID3A. 
Additional potential pathogenic pathways leading to the development of 
CVID were identified. Among these, the death receptor pathway was 
identified by both whole genome sequencing and RNA-seq analyses. This 
finding, coupled with the increased expression of the apoptosis inducing 
receptor gene FAS, and variations in other apoptosis related genes (TNFAIP3 
and TNIP1), suggest dysregulated apoptosis in patients with CVID [165, 
170]. 
A role for defects of the non-homologous end joining (NHEJ) pathway (an 
essential pathways V(D)J recombination and class–switch recombination) in 
the pathogenesis of CVID-like disorders has been hypothesized based on 
observations of an incomplete developmental block in B cell ontogeny in the 
bone marrow of CVID patients compared to healthy subjects [171-173]. van 
Schouwenburg et al. also detected variants in DCLRE1C, PRKDC, RAG2, 
NHEJ1, MRE11A, ATM and NLRP2 which are all important in the NHEJ 
pathway in B cells [165]. 
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Overall, these studies illustrate the utility of GWAS, NGS and RNAseq 
analyses in investigating the genetic etiology/associations with CVID and 
CVID-like disease pointing to a polygenic etiology of these 
immunodeficiencies. 
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2 AIMS 
2.1 GENERAL AIM 
The general aim of the work presented in this thesis was to identify a genetic 
association with common variable immunodeficiency by screening probands 
from consanguineous families to confirm any genetic associations and to 
perform follow up analyses. 
 
2.2 SPECIFIC AIMS 
2.2.1 Paper I 
To functionally characterize the novel CD27 mutations identified and to 
provide a clinically relevant summary of all cases of CD27 deficiency reported. 
2.2.2 Paper II 
To functionally characterize the novel loss-of-function mutation identified in 
the RAC2 gene leading to a CVID-like phenotype. 
2.2.3 Paper III 
To provide a clinically relevant summary of all reported cases of LRBA 
deficiency together with five novel mutations leading to the LRBA deficiency 
phenotype. 
 
2.3 TRANSLATIONAL AIM 
The translational aim of this thesis was to provide clinicians treating patients 
suffering from PIDs with the following: 
1. Updated clinical, laboratory and mutation analysis for selected cases of 
common variable immunodeficiency. 
2. Provide awareness of the feasibility of using whole exome sequencing to 
identify a genetic etiology for PIDs.
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3 MATERIALS AND METHODS 
 
3.1 SELECTION OF PROBANDS 
 
Medical records and family pedigrees were evaluated for patients and family 
members (n =130 families) from multiple medical centers including follow-up 
of previously reported patients. Informed consent was obtained from all patients 
and/or their legal guardians. Ethical permits were obtained from the ethics 
committees of all participating centers. Candidate probands for whole exome 
sequencing were selected based on the clinical history, family history of 
parental consanguinity and availability of clinical samples for DNA extraction 
from the probands and family members. 
3.2 WHOLE EXOME SEQUENCING 
3.2.1 DNA extraction, library preparation and exome sequencing 
 
Genomic DNA was extracted using the salting-out method on peripheral blood 
samples collected from the probands and their family members [174].  Three 
micrograms of genomic DNA was randomly fragmented using the Covaris 
Acoustic System. Adapters were then ligated to both ends of the fragments. The 
adaptor-ligated DNA templates were purified with Agencourt AMPure SPRI 
beads where fragments with an insert size of about 200 bp were excised. 
Extracted DNA was then amplified by the ligation-mediated PCR (LM-PCR), 
purified and hybridized to the Agilent SureSelect Human All Exon 50 Mb kit 
for enrichment. The hybridized fragments were subsequently bound to 
streptavidin beads and non-hybridized fragments were washed off after 24 
hours. Captured LM-PCR products were subjected to quantitative PCR by an 
Agilent 2100 Bioanalyzer to measure the magnitude of the enrichment. Each 
captured library was then loaded on a Hiseq2000 Illumina sequencer according 
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to the protocol of the manufacturer and high-throughput sequencing was 
performed to obtain the desired sequencing depth.  
3.2.2 Read mapping and variant analysis 
 
Processing of raw image files was done using the Consensus Assessment of 
Sequence and Variation software (CASAVA, version 1.7) for base calling using 
default parameters.  Then sequences for each subject were generated as 90-bp 
paired-end reads. The sequenced reads were aligned to the human genome 
reference (UCSC hg 19 version; build 37.1) with SOAP aligner (soap2.21) 
software [175]. This was followed by filtering out duplicated reads and only 
uniquely mapped reads were kept for further analysis. SOAPsnp (version 1.03) 
software  [176]  was then used with the default parameters to assemble the 
consensus sequence and call genotypes in target regions. For single nucleotide 
polymorphism (SNP) quality control, low-quality SNPs that fulfilled one of the 
following four criteria were filtered out:  
(1)  Quailty of genotype < 20  
(2)  A sequencing depth  < 4 
(3)  Estimated copy number > 2 
(4)  Distance from the adjacent SNPs < 5 base pairs.  
The Unified Genotype tool from GATK (version v1.0.4705) [177] was 
employed to detect  small insertions/deletions after alignment of the high-
quality reads to the human reference genome by using the Burrows-Wheeler 
transformation (version 0.5.9-r16) [178]. 
3.2.3 Analysis protocol for exome sequencing results 
 
Synonymous mutations were filtered out and then common variants (frequency 
> 1%) were eliminated. The prioritization of non-synonymous/splice site 
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(NS/SS) changes and insertion/deletions (Indels) was performed according to 
the following criteria: 
1. The presence of homozygous or compound heterozygous variants;  
2. Primary immunodeficiency disease associated genes based on the RAPID 
website (http://rapid.rcai.riken.jp/RAPID/index_html) and in-house 
database;  
3. The core obtained by predictive software scoring the probability of 
pathogenicity (Polyphen-2: http://genetics.bwh.harvard.edu/pph2 and 
SIFT: http://sift.bii.a-star.edu.sg).  
4. Searching genes in the regions previously highlighted by homozygosity 
mapping analysis. 
 
3.3 CONFIRMATORY SANGER SEQUENCING  
 
Confirmatory sequencing for mutations was performed using sequence-specific 
primers using standardized protocols as previously described for CD27 [179], 
RAC2 [94, 180] and LRBA [51]. 
3.4 TRANSMISSION ELECTRON MICROSCOPY 
 
Neutrophil transmission electron microscopy was performed according to the 
previously published method [51]. 
 
3.5 SOLUBLE CD27 ENZYME-LINKED IMMUNOSORBENT ASSAY 
 
The concentration of soluble-CD27 (sCD27) was determined by enzyme-linked 
immunosorbent assay (ELISA) in stored serum samples using the PeliKine 
 14 
Compact
TM
 human soluble CD27 ELISA kit (Sanquin, Amsterdam, The 
Netherlands) followingبtheبmanufacturer’sبinstructions. 
 
3.6 B CELL ACTIVATING FACTOR (BAFF) ELISA  
 
The concentration of soluble BAFF was measured using the Human BAFF 
SimpleStep ELISA
TM
 kit (Abcam, Cambridge, United Kingdom) following the 
manufacturer’sبinstructions. 
3.7 STATISTICAL ANALYSES  
 
Statistical analysis was performed using the SPSS software package v21. One-
sample Kolmogrov-Smirnov test was used to estimate the type of distribution of 
the ELISA data. Parametric and nonparametric analyses were subsequently 
performed based on this evaluation and a p value of less than 0.05 was 
considered statistically significant 
3.8 RAC2 WESTERN BLOTTING 
 
Wild type and RAC2 mutant expressing constructs were generated by 
previously described methods [181]. The expressing constructs were transfected 
intoبhumanبfibroblastبcellبlinesبusingبTurbofectبaccordingبtoبtheبmanufacturer’sب
protocol (Fermentas, Berlington, Ontario, Canada).  
ProteinبsamplesبwereبdilutedبinبLaemmli’sبsampleبbufferب(Bio-Rad, CA, USA), 
and 30 µg of total cell lysates/lane was subjected to 12% sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The resolved proteins 
were transferred onto Amersham Hybond electrogenerated chemiluminescence 
(ECL) Nitrocellulose membranes (Amersham, GE Healthcare, United 
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Kingdom) using a mini-Trans-Blot cell system (Bio-Rad). Following transfer, 
membranes were washed with Tris-buffered saline containing 0.1% Tween-20 
(TBST) and then blocked in Blocking buffer (5% skim milk in TBST) for one 
hour at room temperature. The membranes were then incubated overnight with 
anti-RAC2 rabbit polyclonal carboxy-terminus antibody at a dilution of 1:5000 
(07-604; EMD Millipore, MA, USA) in TBST containing 5% skim milk at 4ºC. 
After washing five times for 5 min in TBST, membranes were incubated with 
anti-Rabbit immunoglobulin conjugated with horseradish peroxidase (HRP) at a 
dilution of  1:50000 (P0399; Dako Agilent Technologies, CA, USA) for one 
hour at room temperature. The membranes were washed four times (10 min per 
wash) with TBST. Finally, proteins were visualized with ECL Plus Western 
Blotting Detection Reagent (Amersham, GE Healthcare, United Kingdom), and 
exposed to Hyperfilm ECL (Amersham, GE Healthcare, United Kingdom). 
3.9 LRBA WESTERN BLOTTING  
 
Peripheral blood mononuclear cell (PBMC) extracts were obtained by standard 
techniques and protein levels were measured using the Micro BCA
TM
 Protein 
Assay Kit according to the manufacturer’s instructions (Thermo Scientific, MA, 
USA). Western blotting was performed according to standard techniques and 
anti-LRBA antibody as previously described [51] with the substitution of the in-
house gel with pre-cast Mini-PROTEAN® TGX
TM
 4%-20 gradient gel (Bio-
Rad, CA, USA). 
3.10  TREC AND KREC ANALYSIS  
 
T-cell recombination excision circles (TREC) and kappa-deleting element 
recombination circle (KREC) analysis was performed according to the 
previously published protocol [182] on DNA samples obtained for whole 
exome sequencing by the salting out method.  
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4 RESULTS AND DISCUSSION 
 
This research project focused on searching for genetic alterations potentially 
contributing to the pathogenesis of primary antibody deficiency by employing 
whole exome sequencing as the primary investigative tool in selected candidate 
probands. 
The search culminated in the identification of ten novel mutations associated 
with CVID, CVID-like disease, lymphoproliferative disease and inflammatory 
bowel disease.  
 
4.1 PAPER I 
 
Novel Mutations in TNFRSF7/CD27: Clinical, Immunologic, and 
Genetic Characterization of Human CD27 Deficiency 
 
4.1.1 Novel mutations resulting in CD27 deficiency 
 
Four novel mutations that resulted in CD27 deficiency were identified: 
 Homozygous missense c.G287A (p.C96Y) 
 Homozygous missense c.C232T (p.R78W) 
 Heterozygous nonsense c.C30A (p.C10X)  
 Compound heterozygous c.G24A - c.C319T ( p.W8X - p.R107C)  
Two homozygous mutations (p.W8X and p.C53Y) resulting in a CD27 
deficiency phenotype had been described previously [92, 93, 146]. The 
identification of these novel mutations correlated with the finding in the 
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previously published patients and also suggested that a compound heterozygous 
mutation can also lead to a CD27 deficiency phenotype. The location of the 
novel mutations and previously identified mutations are illustrated in Figure 1. 
 
 
 
Figure 1. Three-dimensional structure of human CD27 showing the locations of the identified 
mutations. [179] (Paper I) 
 
Analysis of the  c.C319T/p.R107C mutation  in silico using the Scratch Protein 
Predictor [183] showed that it would induce a disulphide bond to form between 
Cysteine residue 107 and Cysteine residue 112, resulting in replacement of the 
bond between Cysteine residue 106 and Cysteine residue 112, potentially 
resulting in the formation of a mis-folded protein.   
The SIFT (Sorting Intolerant From Tolerant) and PolyPhen-2 (Polymorphism 
Phenotyping v2) software programs were used to predict the effect of the 
substitution of an amino acid on protein structure and function.  
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The SIFT (0.04) and PolyPhen-2 (1.000) scores for p.C96Y predicted a 
damaging effect on protein function. The p.C96Y mutation would probably 
abolish the formation of a disulphide bond involved in protein folding [184].  
The SIFT (0.01) and PolyPhen-2 (1.000) scores for mutation p.R78W also 
predicted a damaging effect on protein function.  
For the p.R107C mutation, a damaging effect was predicted by the SIFT score 
(0.02), and a possibly damaging effect was predicted the by PolyPhen-2 score 
(0.767). 
 
4.1.2 Variable phenotype of CD27 deficiency 
 
Although Epstein-Barr virus (EBV) infection, Epstein-Barr virus-associated 
lymphoproliferative disease (EBV-LPD), hemophagocytic lymphohistiocytosis 
(HLH) and malignancy appear to predominate in CD27 deficiency, a single 
genotype appears to result in different phenotypes. Primary antibody deficiency 
was not the dominant feature overall as it occurred in a minority of patients (P1, 
P15 and P17), all of whom had EBV-related clinical features. As with other 
primary immunodeficiencies, environmental factors and modifier genes might 
impact the clinical phenotype. This was striking in the case of the p.C96Y 
mutation in members of two unrelated kindreds (kindreds G and H, Table I in 
Paper I) where siblings P13 and P14 had a milder clinical phenotype compared 
with P15 and P16, despite all patients having the same genotype. These variable 
clinical phenotypes have been observed in other primary immunodeficiencies 
[185-187]. 
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4.1.3 Reduced expression of CD27 
 
A marked reduction of cell surface expression of CD27 was observed in both T 
and B cells (Figures 2 and 3), and decreased soluble CD27 (sCD27) in 
members of kindred H (P15, P16 and family members) (Figure 4). The 
switched memory B lymphocyte panel shows absent expression of surface 
CD27 for patient P16. Other family members (heterozygous) had expression 
levels similar to the father. 
 
 
Figure 2: Flow cytometric lymphocyte immunophenotyping showing the proportion of 
CD21
+ 
and CD27
+
 B cells in the CD19
+
 B-cell fraction was evaluated in P16 (homozygous 
C96Y), the father of P16 (heterozygous C96Y), and in a healthy control. PerCP, peridinin-
chlorophyll-protein complex; PE, Phycoerythrin (Paper I). 
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Figure 3: Flow cytometric lymphocyte immunophenotyping of patients P11, P12, P13, P14 
and their parents compared to healthy controls. Hom, homozygous; Het, heterozygous (Paper 
I). 
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Figure 4  : Comparison of ELISA results of soluble-CD27 between 25 anonymized healthy 
controls and 10 CVID patients without CD27 deficiency, 4 individuals with a heterozygous 
C96Y mutation (measured 4 times) and patient P16 with the homozygous C96Y mutation 
(measured 4 times). 
 
4.1.4 Increased susceptibility to EBV infection and cellular 
features 
 
The increased susceptibility to EBV infection in patients with CD27 deficiency 
manifests as a spectrum of severity including a relatively benign course, 
recovery after therapy or hematopoietic stem cell transplantation (HSCT), 
severe morbidity, and death due to various complications. 
This finding is significant in view of epidemiologic studies indicating that more 
than 95% of adults worldwide have been infected with EBV [188]; and that 
there is a robust life-long immunologic control of EBV infection in 
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immunocompetent individuals dependent on priming of T cells [189, 190]. 
Indeed, studies on murine lymphocytes indicate that there is a significant defect 
of CD8
+ 
T cell priming as a result of CD27 deficiency, which will be discussed. 
In the T cell compartment, CD4
+
 and CD8
+
 T cell subset numbers were normal 
in the majority of cases. This finding is consistent with findings in the murine 
CD27 knockout (CD27 KO) model, where proportions were similar to WT 
(wild type) mice [191]. However, as human beings are the only known natural 
host of EBV [192], drawing conclusions from murine studies with regards to 
this particular susceptibility is extremely challenging.  
Naive CD4
+
 and CD8
+
 T cells constitutively express CD27 and expression is 
upregulated upon activation [193-195]. The difficulty in interpreting the 
consequences of the presence or lack of CD27 stimulation in vivo, isبCD27’s 
relationship with its only natural ligand, CD70, which also functions as a 
receptor for signal transduction in T and B lymphocytes, dendritic cells (DCs) 
and macrophages [195-199]. In vitro studies using lymphocytes transfected 
with either CD27 or CD70 show that both molecules have important roles in 
interaction between T cells and between T cells and B cells, as well as autocrine 
functions [191, 200-203].  
The absolute counts of CD8
+
 T cells were high in four patients, which might be 
due to the timing of analysis during active infection. A reduced proportion of 
CD8
+
CCR7
+
CD45RA
-
CD45RO
+
 T cells was observed in one patient (P16) 
which might be a result of impaired generation and maintenance of EBV-
specific CD8
+
 T cells. Murine studies show impaired secondary cytotoxic CD8
+
 
T cell expansion in CD27 KO mice exposed to lymphocytic choriomeningitis 
virus [204]. 
In vitro analysis of murine CD8
+
 T cells shows that stimulation via the 
CD27/TCR pathway in the absence of signaling via the interleukin-2 receptor 
results in CD8
+
 T cell proliferation without differentiation into effector cells 
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[201]. The enhanced cell survival apparently results from CD27-mediated 
facilitation of interleukin-7α (IL-7α) expression [201].  In vivo, IL-7 is essential 
for the survival of peripheral murine CD8
+
 T cells [205].  
Murine studies also indicate that signaling via CD27 is important for T cell 
survival, particularly by inducing the production of interleukin-2 (IL-2) that 
stimulates CD8
+
 T cells in an autocrine manner enhancing anti-viral and anti-
tumor immunity as a result of increased survival and accumulation in tissue and 
draining lymph nodes [202]. CD27
 
KO mice had significantly lower numbers of 
IL-2
+ 
interferon-γ+ (IFNγ)+ CD8+ T cells in splenic tissue, pulmonary tissue, and 
draining lymph nodes after influenza virus infection [202]. A similar 
mechanism might be involved in human CD27 deficiency, leading to the 
deficiency of an EBV-specific subset of CD8
+
 T cells (both memory and 
effector cells).  
CD27 KO C57BL/6 mice were found to have decreased accumulation of CD8
+
 
and CD4
+
 effector T cells in the lungs, which was in contrast to the normal 
immune response to infection with the influenza virus [203]. The decrease in 
influenza virus-specific CD8
+
 T cells in the lungs was a further indicator that 
CD27 was a major determining factor in the cellular response at the infection 
site. 
Murine studies have also shown that the in vivo role of the CD27-CD70 
costimulatory pathway is non-redundant for the activation of naive CD8
+
 T 
cells [206]. CD27 promotes gene expression toward a Th1 phenotype and 
facilitates the accumulation of antigen-specific CD4
+
 T helper cells at tissue 
sites and priming sites, thus also facilitating an improved supportive capacity 
for a primary cytotoxic CD8
+
 T cell response in a setting of antigen fragment 
cross-presentation [207]. 
Other indirect in vivo observations in murine studies using blockade of CD70, 
indicate that the loss of CD27 costimulation results in inhibition of CD8
+
 T cell 
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priming during viral infections (vesicular stomatitis virus and vaccinia virus) 
and bacterial infection (Listeria monocytogenes) [206]. A similar defect might 
occur in humans where CD8
+
 T cell priming in EBV infection is affected. 
Regarding the B lymphocyte compartment, cell-surface expression of CD27 is 
used in flow cytometry-based lymphocyte subset immunophenotyping of 
memory B cells in order to classify primary immunodeficiencies, including 
CVID [208, 209]. Stimulation of CD27 on human B lymphocytes has been 
linked to the promotion of immunoglobulin production in a coordinated pattern 
related to other surface receptors including CD40 (and its ligand CD154) and 
CD134 (and its ligand OX40) [210, 211]. 
CD27
+
 B lymphocytes appear morphologically and functionally distinct from 
CD27
-
 B lymphocytes. CD27
+
 B lymphocytes are larger and contain more 
abundant cytoplasm, and are present in different stages of the cell cycle;  
whereas CD27
-
 B lymphocytes are smaller and contain scant cytoplasm, and are 
in a single stage of the cell cycle [212, 213]. 
Murine B lymphocytes do not express CD27 at the naive and transitional stages, 
and only begin to express CD27 during the germinal center reaction 
(centroblasts). Somatically mutated B cells do not express CD27 and only a 
minority of memory B cells express CD27 [214]. This is in contrast to human B 
cells, where CD27 is expressed on a larger proportion of germinal center B 
cells, is maintained during differentiation and is expressed on the majority of 
memory B cells [209, 215, 216]. This difference in expression pattern would 
expectedly result in a dramatically different outcome with regards to immune 
responses and subsequent immunoglobulin production. Although 
hypogammaglobulinemia has not been reported in the CD27 KO murine model, 
delayed IgG responses were observed despite influenza virus-specific IgG 
antibody responses [214]. Additionally, the smaller germinal centers observed 
in both human CD27 deficiency [92] and murine CD27 KO lymph nodes [214] 
might indicate a yet unidentified cellular immune defect. 
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Jacquot et al. observed that CVID patients with an extremely low percentage of 
CD27
+
 memory B cells had more severe clinical phenotypes, profound 
hypogammaglobulinemia and reduced peripheral B cells compared to patients 
with a higher percentage of CD27
+
 memory B cells. Additionally, the kinetic B 
cell profiles of two patients failed to upregulate to the levels observed in other 
patients, despite both having a normal percentage of T cells [217].  
Studies on human cell lines have shown that EBV-induced transformation of 
B lymphocytes is prevented by the EBV-specific antibodies in human 
intravenous immunoglobulin (IVIG) [218]. Although the CD27 deficiency 
patients did produce EBV-specific antibodies, the total amount of antibodies 
required to prevent transformation of all transforming B cells might have been 
reduced due to the primary or secondary hypogammaglobulinemia. 
The absence of CD27 does not solely explain the primary 
hypogammaglobulinemia in some patients, who nevertheless mounted a 
specific antibody response to EBV. In certain cases CD27 deficiency might be a 
progressive disease with more severe manifestations occurring as a result of 
deleterious pathophysiological mechanisms secondary to severe EBV infection. 
Regarding NK cells, it has been observed that impairment of NK cell function 
increases anب individual’sب susceptibilityب toبEBVب infectionب andبEBV-associated 
malignancy [189, 219]. CD27 appears to contribute to NK cell physiology at 
multiple levels and, thus impairment at the CD27-CD70 interface would result 
in perturbed function. 
Peripheral blood NK cell function was found to be reduced in the majority of 
patients tested (5/7) and all had EBV-associated clinical manifestations. The 
impaired function might be a direct result of CD27 deficiency or secondary to 
infection with EBV. In addition, impaired function was measured in peripheral 
blood NK cells, which only represents a subset of NK cells. 
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Based on the expression of CD27, two distinct subsets of NK cells exist in both 
murine [220] and human [220-222] lymphocyte populations. In humans, 
approximately 6% of peripheral blood CD3
-
CD56
+
 NK cells express CD27 
[222]; and CD56
high
 NK cells express higher levels of CD27 [223]. The surface 
expression pattern of CD27 appears to be an ontological marker of maturity. 
Stage I to stage III NK cells are CD27
-
, stage IV NK cells are CD27
+
, and stage 
V NK cells are CD27
-
 [222]. 
Activation of human NK cells using recombinant IL-2 results in an upregulated 
expression of CD27, with the highly enriched NK cell population showing less 
upregulation compared to the less enriched population, suggesting that 
interaction with other PBMCs might be required for full NK cell activation 
[223]. CD27
+
 and CD27
-
 NK cells express different levels of NK receptors 
(bothبinhibitoryبandبactivating),بIFNγبandبcytolyticبproteinsب[222]. 
The intensity of surface expression of CD56 is related to that of CD27. CD56
high
 
CD27
high
 NK cells are the dominant population in tonsils and lymph nodes; and 
CD56
low
 CD27
low
 NK cells predominate in peripheral blood [224, 225]. The 
distinct tissue distribution of a given lymphocyte subset might provide a tissue-
specific immune response. Murine NK cells constitutively express CD27 [226]. 
Murine CD27
low 
cells are the dominant NK cell population in peripheral blood; 
form a mixed population with CD27
high
 NK cells in bone marrow; are abundant 
in pulmonary tissue and relatively scarce in lymph nodes [226]. 
Human CD56
high
 CD27
high
 NK cells are poorly cytotoxic [227] which is in 
contrast to murine CD27
high
 NK cells, despite similar expression of NK cell 
receptors on both cells [221]. Murine CD27
low
 NK cells have low proliferative 
capacity [220]. Human and murine CD27
high
 NK cell have been shown to be 
potent producers of IFNγب [220]. In vitro,ب IFNγب productionب afterب ligationب ofب
CD27 on CD56
high
 NK cells is enhanced [228]. A reductionب inبIFNγ levels in 
secondary lymphoid tissues (particularly tonsillar tissue) as a result of CD27 
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deficiency might contribute to predisposition to increased severity of EBV 
infection and induction of EBV-associated malignancy. 
Moreover, both human and murine studies show that the CD27-CD70 
interaction is an important mechanism in immunity to tumors [229-235]. In 
vivo, murine NK cells reject tumor cells that express CD70 [233]. One hundred 
percent of all subtypes of Hodgkin lymphoma have been shown to express 
CD70 [236]. The loss of CD27 expression in patients with CD27 deficiency, 
might thus deprive them of vital immune responses against tumors cells, 
especially those that express CD70. 
Determining the exact role of the loss of CD27 expression will depend on 
analyzing lymphocytes (T, B and NK cells) and other cells at specific 
anatomical sites related to ongoing infection, as well as investigating the 
interaction between lymphocyte subsets that are not conventionally thought to 
contribute to antibody responses (e.g., B cells and NK cells) and which have not 
been extensively studied [237, 238].  The oropharyngeal lymphoid tissue (to 
investigate EBV infection) and bone marrow and mucosal lymphoid tissue (to 
investigate antibody deficiency) should be the primary focus.  
In conclusion, CD27 deficiency results in immunodeficiency with varied 
clinical features. Although our patients represent a relative “knockoutبmodel”بofب
disease, CD27 deficiency cannot strictly be considered a monogenic cause of 
the clinical phenotype(s). 
  
 28 
4.2 PAPER II 
 
RAC2 Loss-of-function Mutation in 2 Siblings with Characteristics 
of Common Variable Immunodeficiency 
 
4.2.1 Identification of a novel mutation in the RAC2 gene 
 
4.2.1.1 W56X mutation 
 
Whole-exome sequencing analysis of DNA from the proband revealed a novel 
homozygous nonsense mutation in codon 56 (W56X) of the RAC2 (Ras-Related 
C3 Botulinum Toxin Substrate 2) gene. This mutation was validated by 
confirmatory Sanger sequencing and was found to be in a homozygous form in 
her brother. The mother carried a heterozygous form of the mutation. DNA 
from their father was not available to confirm if he was a heterozygous carrier, 
however, he would most probably be a carrier given the parental consanguinity.  
4.2.1.2 Immunodeficiency phenotype of RAC2 deficiency 
 
The clinical phenotype of the proband and her sibling (case histories in Paper 
II) contrasted significantly with the primary neutrophil dysfunction phenotype 
observed in the two previously reported patients with the D57N mutation ([239-
241] and Table E4 in Paper II).  
The first reported case was a male infant born at term with delayed separation 
of the umbilical cord who subsequently presented with peri-rectal abscess, and 
peri-umbilical infections from which Escherichia coli and Enterococcus species 
were cultured. The absence of granulation tissue in the wound was noted with 
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subsequent recurrence of the peri-rectal abscess. Complete wound healing was 
only achieved after granulocyte transfusions [240]. 
The second reported patient was an apparently healthy two week old full-term 
male infant, who was found to have reduced TREC counts in the Wisconsin 
statewide Newborn Screening for T cell lymphopenia program [241, 242]. 
Further clinical evaluation revealed leukocytosis, increased neutrophils, and 
CD4
+
 T cell lymphopenia with an increased percentage of memory 
CD4
+
CD45RO
+
 T cells. However, the magnitude of reduction in lymphocyte 
subset counts was not as low as those typically observed in infants suffering 
from severe combined immunodeficiency (SCID). At 26 days of life, the infant 
presented with fever and omphalitis, requiring surgical debridement. At day 56 
he developed a paratracheal abscess requiring drainage. Stenotrophomonas and 
Prevotella species were subsequently grown from the cultures of the abscess. 
Neutrophil chemotaxis was severely reduced in the patient [241]. 
The proband and her brother were born to consanguinous parents and were 
apparently healthy at birth and did not present with soft tissue infections that 
were described in the two unrelated previously reported patients born to non-
consanguinous parents [239-241]. The proband and her brother later manifested 
with recurrent infections, hypogammaglobulinemia, post-streptococcal 
glomerulonephritis, autoimmune hypothyroidism and endocrine hormone 
abnormalities (for details see Paper II).  
In our patients with the novel W56X mutation, the increased levels of 
parathyroid hormone (PTH) in the proband might be linked to RAC2 
deficiency, as human RAC2 (and murine Rac2) expression is mainly 
hematopoietic cell/tissue-specific [243-246]. Osteoclasts are cells of 
hematopoietic origin and are the only cells that possess resorptive function for 
bone modelling [247-250]. Several abnormalities related to osteoclasts occur in 
Rac2 KO mice [251]. These abnormalities include increased trabecular bone 
mass in male mice, increased numbers of osteoclasts per total bone area, 
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increased expression of Rac1 (a separate Rac family protein), an abnormal actin 
cytoskeleton, reduced chemotaxis and an impairment of resorptive capacity. 
Similar defects might have affected osteoclasts in our patients resulting in 
impaired calcium homeostasis.  The proband had a slightly reduced serum 
calcium level of 8.1 mg/dL (normal range: 8.5-10.2 mg/dL), a finding that 
might correspond to the impairment of resorptive capacity present in Rac2 KO 
mice. Bone resorption is an essential mechanism for the maintenance of normal 
calcium levels in blood [252]. Though serial measurements of serial calcium 
were not performed, and more importantly ionized calcium levels were not 
documented, hypocalcemia might have been a trigger for the secretion of 
increasing amounts of PTH through the feedback mechanism that regulates 
blood PTH levels, thus causing secondary hyperparathyroidism [253, 254]. 
Rac2 KO mice have an augmented anabolic response to treatment with 
exogenous PTH, as evident from increased cortical bone thickness and 
increased bone mass density [255]. This increased anabolic response might also 
occur in human oseteoclasts, and might lead to certain pathologic changes. 
The deficiency of growth hormone in the sibling is harder to explain in relation 
to RAC2 deficiency. Growth hormone is secreted by the anterior pituitary gland 
(adenohypophysis)ب andب theب ‘classic’بmodelب ofب theب embryonicب developmentب ofب
the adenohypophysis states a non-neural origin [256]. However, an alternative 
neural origin has been suggested [257]. Another RAC protein, RAC3 is the 
predominant RAC protein expressed in brain tissue, whereas RAC2 is not 
[245]. Investigating the expression pattern of Rac2 in animal models might 
offer some insights into the role Rac2 might play in pituitary function and 
hormone secretion/regulation. 
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4.2.2 Loss of RAC2 protein expression 
 
There was a complete loss of expression of RAC2
W56X
 in transfected human 
fibroblasts (Figure 1C in Paper III). As W56X is a missense mutation the loss of 
expression is expected. This finding is in contrast to the finding of reduced 
expression of RAC2
D57N
 mutant protein that had a dominant negative effect, 
resulting in reductions of neutrophil oxidative metabolism  [239, 240]. 
 
4.2.3  Neutrophil features in RAC2 deficiency 
 
4.2.3.1 Normal cell size 
 
The total volume of cytoplasm (measured in two dimensions) was similar in 
both the healthy control and in the proband's neutrophils (10.1 ± 1.7 µm
2
 and 
10.2 ± 1.4 µm
2
, respectively) indicating no differences in cell size.  
 
4.2.3.2 Numerical abnormalities of neutrophil granules 
 
By comparing the number of primary (azurophilic) granules and secondary 
(specific) granules, a significant reduction in the number of granules was 
observed in proband neutrophils compared to control neutrophils (n = 15 for 
each). 
The average counts of specific and secondary granules were 3.8 ± 0.7/µm
2
 in 
the proband’s neutrophils compared to 5.9 ± 1.3/µm2 inب theبhealthyب control’sب
neutrophils (P = 2.3 × 10
-5
, Student t test).  
Neutrophil granules are classified as primary (azurophilic, peroxidase-positive) 
and secondary (peroxidase-negative) granules [258]. Neutrophils from Rac2 
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KO
 
mice have been observed to show the complete loss of ability to release 
primary granules in response to both physiologic and artificial priming [259]. 
Subsequent murine studies supported this finding, while showing that murine 
secondary granule release was independent of Rac2 function [260, 261]. This 
functional abnormality of absence of primary granule release was also observed 
in the first human case [239], and a later study supported a role for human 
RAC2 in primary granule release [262]. 
A link apparently exists between these (numerical and functional) abnormalities 
of neutrophil granules and impaired cytoskeleton function, which is strongly 
suggested to exist in Rac2/RAC2 deficiency. Human neutrophil phagocytosis 
and (primary and secondary) granule exocytosis are regulated by the actin 
cytoskeleton [263-266]. Murine Rac2 regulates chemotaxis (in both neutrophils 
and macrophages) and appears to be essential for formation of neutrophil 
extracellular traps (NETs), both of which are processes that are thought to be 
dependent of cytoskeletal function [243, 267-269]. NETs formation is also a 
feature of human neutrophils [265, 270]. In addition, studies on murine 
macrophages expressing the dominant negative Rac2
D57N
 mutant protein show 
decreased micropinocytosis, another process dependent on a functional 
cytoskeleton [271]. 
Murine Rac2, in contrast to RAC2 in human neutrophils, is not the predominant 
Rac protein in murine neutrophils and is expressed at similar levels to its 
isoform Rac1 [272]. Thus, it is plausible that a compensatory role for Rac1 
diminishes the effects of Rac2 deficiency on cytoskeletal function relating to 
granule regulation in murine neutrophils, but which does not occur in human 
neutrophils, thus resulting in the abnormalities observed in our patient. 
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4.2.3.3 Abnormal secondary granule morphology 
 
The shape of the secondary granules in the proband’sب neutrophils was often 
more elongated or collapsed compared to the control (Figure 5c-d). 
 
4.2.3.4 Increased cytoplasmic inclusions 
 
Dense multi-membrane cytoplasmic inclusions wereبobservedبinبtheبproband’sب
neutrophils (Figure 5a and e) which were not present in control neutrophils 
(Figure 5b and f). These inclusions were interpreted to be autophagosomes.  
Rac2 (and RAC2) protein has not been linked to altered autophagy. However, a 
decreased level of autophagy has been observed in cells of a human HeLa cell 
line transfected to overexpress RAC3 [273]. Perturbed RAC3 activity has been 
linked to breast cancer [274] and prostate cancer [275]. 
 
4.2.3.5 Abnormal neutrophil chemotaxis 
 
Neutrophil chemotaxis of the sibling was mildly reduced when compared to 
reference ranges (Table 1 in Paper II). This is in contrast to the marked 
reduction in neutrophil chemotaxis observed in the patients with the RAC2
D57N
 
dominant negative mutant protein [239-241]. 
4.2.4 Increased serum BAFF levels 
 
Serum levels of BAFF in two independent samples from the living sibling were 
analyzed and a 5 to15 fold higher level of BAFF was detected in the patient as 
compared to controls (6.9 ng/mL and 2.3 ng/mL; controls 0.41-0.47 ng/mL). 
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Elevation of serum BAFF has been observed in autoimmune thyroid disease 
[276] and in chronic urticaria [277]. 
 
4.2.5 RAC2 deficiency and other leukocytes 
 
4.2.5.1 Lymphocyte abnormalities 
 
The decreased recent thymic emigrants, relative B lymphopenia and the 
impaired antibody production in our patients support a role of RAC2 in T- and 
B-cell development and function, as evidenced by murine studies [278-280] as 
well as some T- and B-lymphopenias observed in the second reported patient 
carrying the D57N mutation [241].  
Murine studies indicate that both Rac1 and Rac2 have redundant, but critical, 
parts to play in T cell development [281]. Rac2 deficiency has been linked to 
defective immune tolerance in mice due to impairment of the restimulation-
induced cell death (RICD) mechanism in T cells [282]. Potential impairment of 
peripheral immune tolerance in our patients with the W56X mutation could 
account for the autoimmune hypothyroidism common to both siblings. RAC2 
has been suggested to be a susceptibility gene for the development of 
autoimmune diseases based on studies of haplotype analysis of patients with 
Crohn’sبdisease,بmultipleبsclerosisبandبageبmatchedبhealthyبcontrolsبwhoبwereب
all of (Italian) Caucasian ethnicity [283].  
Rac1 and Rac2 are required for adequate generation of the common lymphocyte 
progenitor in murine bone marrow [281]. However, in contrast to our patients, 
Rac2 KO C57BL/6 mice showed a 40% increase in the proportions of 
peripheral blood B cells [280]. Additionally, these mice had reduced bone 
marrow B cell counts, due to reduced recirculating  B220
high
sIgM
+
 B cells, and 
absent splenic marginal zone (MZ) B cells; and reduced CD5
+
sIgM
+
 peritoneal 
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B-1a lymphocytes [280]. These mice also showed 2-8 fold elevations of IgG1 
and IgG2b, which also contrasted with the normal levels in the proband and 
reduced levels observed in the sibling. 
Murine Rac2 is a key protein in the downstream signaling cascade after B cell 
receptor (BCR) antigen recognition [284]. The activation of Rac2 and Rap1 
connects BCR-proximal signaling with activation of leukocyte function-
associated antigen-1 (LFA-1)-mediated adhesion facilitating the formation of 
immunological synapses [284]. Human RAC2 might also have a similar 
downstream role in BCR signaling and immunological synapse formation, and 
thus a deficiency might directly contribute antibody deficiency. 
4.2.5.2 Mast cells 
 
The urticaria may be related to the significant impairment of mast cell functions 
observed in murine studies. Rac2 is abundantly expressed in murine mast cells 
and is required for exocytosis in these cells [285]. Murine Rac2
 
KO bone 
marrow-derived mast cells have reduced expression of the mouse mast cell 
protease 7 (MMCP-7) gene, a major component of the secretory granules of 
mature mast cells. The impaired mast cell tryptases, especially MMCP-7, are 
responsible for airway smooth muscle hyper responsiveness and other allergic 
reactions, as well as regulate fibrin-platelet clot formation [286]. However, 
pinpointing a specific mechanism leading to urticaria will require additional 
investigation. 
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Figure 5. Transmission electron micrographs of neutrophils: a) proband neutrophil: 
cytoplasmic inclusions (arrow). b) control neutrophil, normal ultrastructure. c) proband 
neutrophil: fewer cytoplasmic granules, with the majority secondary granules displaying an 
abnormal shape (arrow). d) control neutrophil: normal, rounded secondary granules (arrow). 
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e) proband neutrophil: cytoplasmic inclusion, showing multi membrane structure (arrow) 
surrounded by a double membrane (arrowhead).  f) control neutrophil: normal ultrastructure. 
N, nucleus. (Paper II). 
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PAPER III 
 
Spectrum of Phenotypes Associated with Mutations in LRBA 
 
This review provided a summary of previously reported cases of LRBA 
deficiency [51, 142, 149, 287-293] in addition to case histories and mutation 
analysis of five novel LRBA mutations. 
4.2.6 Clinical features of LRBA deficiency 
 
The clinical features of patients in this review correlate with those recently 
found by Gámez-Díaz et al [294] and Lo et al [295]. Although Gámez-Díaz et 
al. grouped enteropathy and autoimmunity together; the most common clinical 
features (chronic diarrhea, autoimmune disease, hypogammaglobulinemia, 
respiratory tract infections) were in line with our findings. 
4.2.6.1 LRBA deficiency present in early childhood 
 
This study shows that LRBA deficiency is a disorder that presents in childhood, 
an observation that has been confirmed in other studies [294, 295].  
The presenting features are most commonly gastrointestinal, autoimmunity-
related or infectious, with significant overlapping of clinical manifestations 
(Figure 6). 
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Figure 6. Venn diagram illustrating the percentages of overlap of clinical 
phenotypes among patients with LRBA deficiency (Paper III).  
4.2.6.2 ‘Asymptomatic’ phenotype of LRBA deficiency 
 
One of the unexpected findings of this review was that two patients (P22 and 
P26), both from different kindreds and with symptomatic siblings carrying the 
homozygous mutations p.S2713fs*13 and  p.S1605X, respectively, were 
asymptomatic at the time of analysis (P22 had been completely asymptomatic 
despite lymphopenia [288], and P26 was a clinically well adult with the 
exception of some respiratory infections during childhood) and neither 
expressed the LRBA protein on Western blot analysis ([288] and Figure 1G in 
Paper III). This finding shows that, like other PIDs, LRBA deficiency in 
individuals with the same genotype mightبhaveبaبrelativelyب‘benign’بphenotype. 
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4.2.6.3 Neurologic complications 
 
A striking feature of LRBA deficiency is that more than a fifth of the patients 
had neurological complications. Despite being from different kindreds and 
having distinct genotypes, the similarity of neurologic complications warrants 
special attention for clinicians. 
Radiologic evaluation of patients P1 and P3 showed cerebral granulomas (P3 
also suffered seizures); patients P28 and P31 both suffered unilateral optic 
nerve atrophy; and patient P29 developed a lesion in the parietal lobe. 
Myasthenia gravis in patient P5 might be categorized as an autoimmune 
disease; however, notwithstanding that, approximately 20% of the LRBA 
deficiency patients did develop neurologic conditions. In their cohort of 22 
LRBA deficiency patients, Gámez-Díaz et al mention only one patient with 
neurologic/psychiatric features and one patient with deafness [294]; and Lo at 
el, mention one patient with seizures [295]. 
Histologic analysis of human neuronal tissue (including glial and neuronal 
cells) reveals that LRBA is expressed in cerebral, cerebellar and hippocampal 
tissue [296]. The role of the LRBA protein deficiency has been thought to be 
limited to immune dysfunction in lymphoid tissues [51], however, in view of 
these neurologic features, the role of LRBA in neuronal tissue should be 
investigated.  
 
4.2.7 Novel LRBA mutations 
 
Five novel mutations were identified using WES and presented with the clinical 
and laboratory findings form previously published cases. The novel mutations 
are presented in Table 1. 
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All patients with novel mutations (P24-P31) were born to consanguinous 
parents. 
Table 1. Summary of clinical data in patients with novel mutations in LRBA deficiency. 
 
Patient Sex Ethnicity 
Age of 
onset 
(years) 
Mutation Main phenotype 
P24 F Iranian 3 c.1014+1 C>T HGG, RTI, AID, OM 
P25 M Iranian 2 p.S1605X HGG, RTI, CD, OM 
P26 M Iranian NA p.S1605X 
Asymptomatic 
(past RTI) 
P27 M Iranian 2 p.R182X HGG, CD, AID, OM 
P28 M Iranian 0.2 enoN dNtNetNd HGG, RTI, CD, OM 
P29 F Lebanese 3 p.N988fs*7 HGG,RTI, OM 
P30 F Iranian 6 c.4729+2insA HGG, RTI, AID, OM 
P31 F Iranian 13 c.4729+2insA AID, OM, RTI 
 
M, male; F, female; HGG, hypogammaglobulinemia; RTI, respiratory tract infections; AID, 
autoimmune disease; OM, organomegaly; CD, chronic diarrhea; NA, not applicable. 
 
4.2.7.1 Novel mutations: Loss of LRBA protein expression  
 
Western blot analyses from patients P25-P28 and P30-31 showed complete loss 
of expression (Figure 1G in Paper III). These findings are in line with the recent 
findings of Gámez-Díaz et al [294] who identified both homozygous and 
compound heterozygous mutations leading to loss of expression of LRBA. 
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5 CONCLUSIONS AND FUTURE PERSPECTIVES 
 
5.1 OVERALL CONCLUSIONS 
 
 The spectrum of disorders encompassing PADs, represented by CVID 
appear to be ever-expanding, particularly as the definition of CVID 
remains fluid. 
 
 The novel mutations identified in this work indicate the viariable 
genotype-phenotype relation, as observed in other PIDs. 
 
 
 WES is an effective method to identify mutations resulting in 
immunodeficiencies and other disorders. 
 
5.2 CONCLUSIONS FROM INDIVIDUAL PAPERS 
 
 Paper I 
Homozygous and heterozygous mutations affecting the CD27 gene 
predispose to the occurrence of EBV infections together with other 
infections in individuals with or without hypogammaglobulinemia 
causing significant morbidity and high mortality. CD27 deficiency 
should be considered in the differential diagnosis of all cases regardless 
of consanguinity. CD27 expression on lymphocytes should be 
implemented as a diagnostic screening test for all patients with a history 
of clinically severe EBV infection, lymphomas, or both, and in all cases 
of atypical EBV infection. Comprehensive immunologic, serologic and 
molecular testing for EBV infection and primary immunodeficiency 
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should be performed, in addition to a complete physical examination, 
with particular emphasis on considering atypical features of EBV 
infection.  
 Paper II 
The W56X nonsense mutation is a novel mutation affecting the RAC2 
gene associated with a CVID-like disorder, autoimmunity and neutrophil 
granule abnormalities.  
 Paper III 
LRBA deficiency might result in a variable clinical phenotype and should 
be considered in the clinical evaluation of CVID and CVID-like 
disorders. 
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5.3 FUTURE PRERSPECTIVES 
 
As new patients are being diagnosed with mutations in CD27, RAC2 and LRBA, 
compiling the information will allow for pinpointing the precise defect(s) by 
genetic, biochemical and cellular analyses. We are now in the process of 
proposing a registry on CD27 deficiency to increase awareness among 
clinicians for finding and collecting patient samples and data.  The proposal will 
be presented at the upcoming meetings of the German, Austrian and Swiss 
Pediatric Immunologists (API) and the European Society for 
Immunodeficiencies (ESID). 
Both human and animal studies are required to identify novel pathways/defects 
that CD27 (and CD70), RAC2 and LRBA are involved in and the subsequent 
function/dysfunction at the cellular and/or systemic level. Ex vivo studies might 
offerبparticularبinsightsبintoبtheseبaspects,بgivenبthatبmurineبmodelsبmayب“sub-
optimally”بreflect their roles in humans. 
The characterization of distinct genes and mutations contributing to the 
pathogenesis of primary antibody deficiency and other primary 
immunodeficiencies will prompt both the designing of more accurate diagnostic 
tools and the targeted therapeutic correction of genetic errors at the molecular 
level before or during the early stages of clinical symptoms and signs, thus 
preventing their effects from progressing to systemic complications. Indeed, 
mutation-targeted therapies are now being developed that mitigate the 
pathological mutation at the nuclear level, based on the accurate 
characterization of mutations. 
Examples of such targeted therapies include read-through compounds and 
chimeric RNA/DNA oligonucleotides (chimeraplasts) that are already being 
developed for the treatment of genetic diseases other than primary 
immunodeficiencies [297].  
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The conventional difficulty encountered in clinical practice in screening for 
mutations in multiple PID genes can now be overcome in a cost-effective 
manner using NGS, either employing WES, WGS or a targetedب “chip”ب
sequencing of PID-associated genes. This analytic approach has proved 
valuable in cases with informative pedigrees (parental consanguinity) as well as 
those with other cases. 
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6 LAY SUMMARY 
 
Let’sبthinkبofبeachبcellبinبaبlivingبcreatureبasبaبcomputer;بandبrememberبthatبaب
computer can only function properly as long as it has a good (software) 
operating program. 
All living creatures possess a master software program molecule called 
deoxyribonucleic acid (DNA) within each cell, based on which all the functions 
of the cell are orchestrated and organized. Cells specialize and multiply forming 
bodily systems that must work in harmony for the creature to function normally 
in its environment. 
If we think of the human body as a nation, then like any nation composed of 
billions of inhabitants (cells), the body must be protected by an efficient 
combined defense and fighting force equipped with deterrent barriers and 
weapons. The immune system represents this system in the human body. It is 
composed of what you might think of as an administrative command, military 
academies, armed forces, weapons factories and support structures, the quality 
of which are directly or indirectly dependent on that master program coded in 
DNA. 
Enemies that attack the body might be foreign (bacteria, viruses and parasites), 
domestic (cancer) or a combination of both. Sometimes, a native inhabitant (a 
cell) will join forces with a foreign agent (a virus), transforming the former into 
a cancer cell. An example of such a foreign agent is the Epstein-Barr virus 
(EBV). Most of us have been infected with itبandبdon’tبrealizeبitبorبjustبhad a 
brief illness thatبwe’veبlongبforgotبabout. It is the virus that causes the disease 
nicknamedب“mono”,ب“kissingبdisease”بorب“glandularبfever”.بOnceبweبhaveبhadب
it, we develop life-long protective immunity to it (if we have healthy immune 
systems). Sometimes EBV joins forces with a cell, turning that cell into a 
cancer cell. Hodgkin lymphoma is one example of this phenomenon. 
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If the immune system is defective due to a problem relating to DNA, then the 
defectب isبcalledب ‘primaryب immunodeficiency’. That problem is often related to 
theبorderبofبtheب‘code’بofبDNA.بThinkبofبDNAبasبtheبveryبparagraph you are 
reading right now. A change or addition of a single letter can change the 
meaning of the word, and then also change the meaning of the sentence. For 
example, ‘fat’بbecomesب‘fit’,ب ‘cat’بbecomesب‘bat’,بandب ‘slim’بbecomes ‘slime’. 
This defect is known asبaب‘mutation’. 
A healthy person generally recovers from infections because the immune 
system fights back, eliminating or destroying the harmful agents. If a person has 
a primary immunodeficiency caused by a mutation, then the story of the 
infection changes. For example, instead of recovering from EBV infection, the 
infection becomes really severe, turns body cells into cancer cells, causes 
medical complications or even leads to the person’sبdeath. 
In order to identify the defects within the immune system, we need special 
tools. The most modern tool we have today is next generation sequencing 
(NGS). This basically gives us the ability to sequence (read) the DNA code just 
as a computer reads zeros and ones. In the past, sequencing a tiny fragment of 
DNA took months or years to do. NGS technology has now helped us sequence 
much more DNA in a much shorter period (days or weeks).  
In this study, my colleagues and I, gathered medical records, blood samples and 
DNA specimens from hundreds of patients and members of their families. 
Using NGS, we were able to identify several mutations in DNA that we think 
contributed to our patients developing the diseases that they suffered from. We 
then performed additional medical tests to determine the impact these mutations 
might have had on their immune systems. We identified mutations in CD27, 
RAC2 and LRBA, all of which are fragments of DNA (genes) that encode 
molecules that function in cells of the immune system. The patients with CD27 
mutations, suffered from severe EBV infections, Hodgkin lymphoma and other 
diseases resembling lymphoma (Paper I). The sister and brother with the RAC2 
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mutation suffered from multiple infections, kidney disease and thyroid disease 
(Paper II). Finally, the patients with LRBA mutations suffered from multiple 
health problems which included infections and chronic diarrhea (Paper III). 
We hope that these discoveries will help health care professionals and scientists 
all over the world to quickly diagnose new patients with primary 
immunodeficiency, develop new therapies, and perhaps even prevent potential 
patients from getting disease by pre-emptively treating them before they 
develop symptoms. 
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7 LAY SUMMARY IN SWEDISH ‘SAMMANFATTNING FÖR 
LEKMÄN’ 
A translation of the lay summary by Gustav Östervall 
 
Låt oss tänka på varje enskild cell i en levande varelse som en dator; och 
komma ihåg att en dator endast kan fungera ordentligt om den har en mjukvara 
av hög kvalitet.  
Alla levande varelser har deoxyribonukleinsyra (DNA), en molekyl av 
mjukvara inuti varje enskild cell som ligger till grund för hur samtliga av 
cellens funktioner är organiserade. Genom att specialisera sig och föröka sig 
formar celler kroppsliga system och dessa system måste fungera i harmoni för 
att varelsen skall fungera normalt i sin miljö.  
Om vi föreställer oss den mänskliga kroppen som en nation, så måste kroppen 
liksom vilken annan nation som helst, bestående av flera miljarder invånare 
(celler i detta fall), beskyddas med hjälp av en militärstyrka utrustat med vapen 
och avskräckande barriärer. Det immunologiska systemet är den mänskliga 
kroppens motsvarighet till en sådan militärstyrka. Immunsystemet utgörs av vad 
du kan föreställa dig motsvara en administrativ myndighet, beväpnade styrkor, 
vapenfabriker och stödstrukturer, vilkas kvalitet är direkt eller indirekt beroende 
av mjukvaran DNA.  
Fienderna som angriper kroppen kan vara främlingar (bakterier, virus och 
parasiter), inhemska (cancer) eller en kombination av båda. Ibland kan en 
invånare (en cell) förena sig med ett för kroppen främmande agens (t. ex. ett 
virus) och omvandlas till en cancercell. Ett exempel på ett sådant främmande 
agens är Epstein-Barr-virus (EBV). Merparten av oss har varit infekterade med 
detta virus utan att ha märkt det eller med en övergående allmän 
sjukdomskänsla som följd. Det är detta virus som orsakar sjukdomen känt som 
“körtelfeber”ب iبdagligtب tal.بEfterب attب viبdrabbatsب avب infektionenبutvecklarبviب enب
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livslång immunitet mot EBV (förutsatt att vårt immunförsvar är friskt). Ibland 
kan detta virus alliera sig med en cell och omvandla denna cell till en 
cancercell. Hodgkins lymfom är ett av dessa sjukdomar. 
Om immunsystemets funktion felar och problemet har sin grund i DNA kallas 
tillståndetب förب ‘primärب immunbrist’.ب Dettaب problem är oftast relaterat till den 
ordning med vilket DNA kodas. Föreställ dig att det textstycke du nu läser 
motsvarar DNA. Att så lite som en enda bokstav ersätts av en annan eller att 
ytterligare en bokstav läggs till kan förändra betydelsen för hela ordet och 
därmedبhelaبfrasen.بTillبexempelبattبordetب“fet”بblirب“fat”,ب“katt”بtillبordetب“hatt”ب
ochب“mat”بblirب“matt”.بDennaبdefektبbenämnsبmutation. 
En frisk individ återhämtar sig vanligtvis från infektioner tack vare att 
immunsystemet slåss tillbaks, förstör och eliminerar skadliga agens. 
Förutsättningarna förändras dock om individen ifråga är drabbad av primär 
immunbrist orsakat av mutationer. Istället för att tillfriskna från en infektion 
med EBV så blir infektionen extremt allvarlig med omvandling av kroppsegna 
celler till cancerceller och kan framkalla medicinska komplikationer eller till 
och med resultera i dödsfall.  
I syfte att kunna identifiera defekter i immunsystemet fordras speciella verktyg. 
Det mest moderna verktyget vi idag använder oss av ärب “massivب parallellب
sekvensering”ب (NGS;ب “nextب generationب sequencing”)ب avب DNA.ب Dettaب gerب ossب
möjligheten att sekvensera (avläsa) DNA-koden på samma sätt som en dator 
avläser ettor och nollor. Förr i tiden tog det månader eller åratal att sekvensera 
ett litet DNA-fragment. Ny teknologi har numera gjort det möjligt för oss att 
sekvensera betydligt större mängder DNA inom kortare tidsramar (dagar eller 
veckor).  
Jag och mina kolleger samlade i denna studie ihop patientjournaler, blodprover 
och DNA-exemplar från hundratals patienter samt deras familjemedlemmar. 
Med hjälp av NGS-teknik identifierade vi flertalet mutationer i DNA som vi 
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anser bidrog till patienternas sjukdomsutveckling. Därefter utförde vi ytteligare 
medicinska tester i syfte att utröna den grad av påverkan mutationerna ifråga 
hade på immunsystemet. Vi identifierade mutationer i CD27, RAC2 och LRBA, 
av vilka samtliga är DNA-fragment (gener) som kodar för de molekyler som 
uppfyller funktioner i immuncellerna. Patienterna med mutationer i CD27 led 
av extrema EBV-infektioner, Hodgkins lymfom och sjukdomar som liknar 
lymfom (Papper I). Syskonparet, en syster och en bror, med mutation i RAC2 
hade multipla infektioner och njursjukdom (Papper II). De patienter med 
mutationer i LRBA led av multipla hälsoproblem, inklusive infektioner och 
kronisk diarré (Papper III). 
Vi hoppas att dessa upptäckter skall underlätta för vårdgivare och forskare att i 
tidigt skede diagnosticera nya patienter med primär immunbrist, att utveckla 
nya behandlingar och förhoppningsvis till och med förhindra att 
högriskindivider drabbas av sjukdom genom att behandla dem innan de 
utvecklar symtom.  
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8 A TRANSLATION OF THE TITLE(S) INTO ARABIC (THESIS AND 
PAPERS) 
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